Home Science MIRAM® Kit Clinical Studies News Team Careers Contact

We proudly sponsor a series of clinical studies to evaluate our liquid biopsy across cancers

LEV87A

Multi-Cancer Early Detection in Asymptomatic Adults

LEVANTIS-0087A (LEV87A) is a retrospective population cohort-based nested case-control study to validate the performance of the free GAGome-based MCED tests in adults asymptomatic for cancer with no recent history of cancer.

LEV93A

Multi-Cancer Early Detection in High-Risk Adults

LEVANTIS-0093A (LEV93A) is a prospective observational cohort study to validate the performance of the plasma free GAGome MCED test in 55 to 80 years old adults with significant smoking history and thus at high risk of developing cancer (“high-risk adults”).

LEV65

Multi-Cancer Early Detection in Firefighters

LEVANTIS-0065 (LEV65) is a prospective observational cohort study to explore the performance of the combined free GAGome MCED test in adults who are actively employed as firefighters in comparison to other MCED tests.

AUR87A

Surveillance for Clear Cell Renal Cell Carcinoma Recurrence

AURORAX-0087A (AUR87A) is a prospective multi-center observational cohort study to validate the performance of the urine free GAGome RCC test for the early detection of recurrence after curative intent surgery in patients with high or intermediate risk clear cell renal cell carcinoma.

PREDI-LYNCH

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome

PREDI-LYNCH aims to develop and validate non-invasive, accurate, and cost-effective liquid biopsy tests to detect cancer at its earliest stages in Lynch Syndrome carriers. By moving beyond traditional, often invasive diagnostic methods, the project seeks to deliver a more acceptable and scalable solution for long-term cancer surveillance.

AUR93A

Prognosis of Muscle-Invasive Bladder Cancer

AURORAX-0093A (AUR93A) is a prospective observational cohort study to develop free GAGome-based tests for the prognosis of muscle-invasive bladder cancer patients elected for neo-adjuvant chemotherapy before radical cystectomy.

LEV45A

Effect of Pre-Analytical Conditions for GAGome testing

This study aims to collect urine samples from healthy people to understand the best conditions for Elypta's test regarding how urine samples are taken, processed, and stored.

Backed by

We welcome partnerships with academia to explore clinical applications as well as industry for the development of companion diagnostics.

We welcome interest from investors and are happy to provide more information on our plans on request.

We are always looking to interact with top talents interested in joining our development team.